Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05053230 · ClinicalTrials.gov registry record · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
A NA study of Ovarian Cancer and Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 480
- Enrollment target
- 7
- Study locations
NCT05053230: Recruiting NA study of Ovarian Cancer and Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05053230 is a NA study of Ovarian Cancer and Melanoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 480 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (34% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05053230, a NA study of Ovarian Cancer and Melanoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 480 participants
- Enrollment target
- 7
- Study locations
Study Summary
The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.
Primary Outcome
Primary outcome will be measured by the average fatigue severity measured by the Brief Fatigue Inventory (BFI). The BFI is a 9-item instrument designed to assess one construct of fatigue severity in cancer and non-cancer populations. Three items ask patients to rate the severity of their fatigue at its "worst," "usual," and "now" during normal waking hours, with 0 being "no fatigue" and 10 being "fatigue as bad as you can imagine." Six items assess the amount that fatigue has interfered with dif
Conditions Studied
Interventions
- BEHAVIORAL Enhanced usual care
- BEHAVIORAL IM@Home
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2026-09-20 |
| Phase | NA |
What NCT05053230 shows while recruiting
NCT05053230 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (34% lower).
The record links to 8 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enhanced usual care is the first listed.
NCT05053230 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT05053230 about?
NCT05053230 is a clinical study titled "A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer". The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and e...
What is the current status of trial NCT05053230?
This trial is currently recruiting. It is a NA study. The enrollment target is 480 participants. The study started on 2021-09-20. Estimated completion is 2026-09-20.
What conditions does trial NCT05053230 study?
This clinical trial studies the following conditions: Ovarian Cancer, Melanoma, Head and Neck Cancer, Gynecologic Cancer, Thoracic Cancer.
What interventions are being tested in trial NCT05053230?
The interventions under investigation include: Enhanced usual care (BEHAVIORAL), IM@Home (BEHAVIORAL).
Who is sponsoring clinical trial NCT05053230?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05053230 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05053230's enrollment target sits among peer trials
480 53rd of 322 higher than 270 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
RECRUITING · NA
-
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
RECRUITING · NA
-
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
RECRUITING · NA
-
Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05279300 · 480 participants · Phase 1
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI